Ethical and Legal Aspects of Pandemics During COVID‐19 and Beyond for the Hepatology Community
Dirk J. Leeuwen – 21 July 2021
Salidroside Activates the AMP‐Activated Protein Kinase Pathway to Suppress Nonalcoholic Steatohepatitis in Mice
Manli Hu, Dingran Zhang, Hongyang Xu, Yan Zhang, Hongjie Shi, Xiaoli Huang, Xinhui Wang, Yan Wu, Zhili Qi – 21 July 2021
Mitochondrial Hepatopathies
Hana Alharbi, Jessica R.C. Priestley, Benjamin J. Wilkins, Rebecca D. Ganetzky – 21 July 2021
Assessment of Sarcopenia in Chronic Liver Disease: Indian Perspective
Abhinav Anand, Anoop Saraya – 21 July 2021
HBV Genotype: A Significant Risk Factor in Determining Which Patients With Chronic HBV Infection Should Undergo Surveillance for HCC: The Hepatitis B Alaska Study
Brian J. McMahon, Leisha D. Nolen, Mary Snowball, Chriss Homan, Susan Negus, Elena Roik, Philip R. Spradling, Dana Bruden – 21 July 2021
Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell–Mediated Antitumor Immunity Through PD‐L1
Noreen Nog‐Qin Chui, Jacinth Wing‐Sum Cheu, Vincent Wai‐Hin Yuen, David Kung‐Chun Chiu, Chi‐Ching Goh, Derek Lee, Misty Shuo Zhang, Irene Oi‐Lin Ng, Carmen Chak‐Lui Wong – 20 July 2021 – Liver cancers consist primarily of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Immune checkpoint inhibitors have emerged as promising therapeutic agents against liver cancers. Programmed cell death protein 1 (PD‐1) is an immunoinhibitory receptor present on T cells that interacts with its ligand programmed death‐ligand 1 (PD‐L1) found on cancer cells.
Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID‐19 Infection
Zobair M. Younossi, Maria Stepanova, Brian Lam, Rebecca Cable, Sean Felix, Thomas Jeffers, Elena Younossi, Huong Pham, Manirath Srishord, Patrick Austin, Michael Estep, Kathy Terra, Carey Escheik, Leyla Avila, Pegah Golabi, Andrej Kolacevski, Andrei Racila, Linda Henry, Lynn Gerber – 20 July 2021 – The impact of the coronavirus disease 2019 (COVID‐19) pandemic among patients with chronic liver disease is unknown.
Modeling PNPLA3‐Associated NAFLD Using Human‐Induced Pluripotent Stem Cells
Samantha G. Tilson, Carola M. Morell, An‐Sofie Lenaerts, Seung Bum Park, Zongyi Hu, Benjamin Jenkins, Albert Koulman, T. Jake Liang, Ludovic Vallier – 19 July 2021
IL‐1β‐Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up‐regulating Programmed Death Ligand 1 and Colony‐Stimulating Factor 1
Qin He, Mei Liu, Wenjie Huang, Xiaoping Chen, Bixiang Zhang, Tongyue Zhang, Yijun Wang, Danfei Liu, Meng Xie, Xiaoyu Ji, Mengyu Sun, Dean Tian, Limin Xia – 19 July 2021
COVID‐19 and the Uncovering of Health Care Disparities in the United States, United Kingdom and Canada: Call to Action
Aftab Ala, Julius Wilder, Naudia L. Jonassaint, Carla S. Coffin, Carla Brady, Andrew Reynolds, Michael L. Schilsky – 19 July 2021 – The coronavirus disease 2019 (COVID‐19) pandemic created a crisis that disproportionately affected populations already disadvantaged with respect to access to health care systems and adequate medical care and treatments. Understanding how and where health care disparities are most widespread is an important starting point for exploring opportunities to mitigate such disparities, especially within our patient population with liver disease.